BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36650499)

  • 1. Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
    Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
    Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
    Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
    Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
    Mansour MR; Abraham BJ; Anders L; Berezovskaya A; Gutierrez A; Durbin AD; Etchin J; Lawton L; Sallan SE; Silverman LB; Loh ML; Hunger SP; Sanda T; Young RA; Look AT
    Science; 2014 Dec; 346(6215):1373-7. PubMed ID: 25394790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia.
    Patel B; Kang Y; Cui K; Litt M; Riberio MS; Deng C; Salz T; Casada S; Fu X; Qiu Y; Zhao K; Huang S
    Leukemia; 2014 Feb; 28(2):349-61. PubMed ID: 23698277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.
    Smith C; Goyal A; Weichenhan D; Allemand E; Mayakonda A; Toprak U; Riedel A; Balducci E; Manojkumar M; Pejkovska A; Mücke O; Sollier E; Bakr A; Breuer K; Lutsik P; Hermine O; Spicuglia S; Asnafi V; Plass C; Touzart A
    Haematologica; 2023 May; 108(5):1259-1271. PubMed ID: 36632736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX1 is required for oncogenic
    Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
    Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia.
    Lim FQ; Chan AS; Yokomori R; Huang XZ; Theardy MS; Yeoh AEJ; Tan SH; Sanda T
    Haematologica; 2023 Feb; 108(2):367-381. PubMed ID: 36073513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.
    Mets E; Van der Meulen J; Van Peer G; Boice M; Mestdagh P; Van de Walle I; Lammens T; Goossens S; De Moerloose B; Benoit Y; Van Roy N; Clappier E; Poppe B; Vandesompele J; Wendel HG; Taghon T; Rondou P; Soulier J; Van Vlierberghe P; Speleman F
    Leukemia; 2015 Apr; 29(4):798-806. PubMed ID: 25231743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia.
    Sanda T; Lawton LN; Barrasa MI; Fan ZP; Kohlhammer H; Gutierrez A; Ma W; Tatarek J; Ahn Y; Kelliher MA; Jamieson CH; Staudt LM; Young RA; Look AT
    Cancer Cell; 2012 Aug; 22(2):209-21. PubMed ID: 22897851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
    Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
    J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S1P-S1PR3-RAS promotes the progression of S1PR3
    Zhu D; Jiang T; Ma D; Zhang H; Zhang J; Lv W; Gong M; Wang H; Liu Z; Su H; Zeng L; Liu S; Tang S; Yang B; Tshavuka FI; Fu G; Liu Z; Peng D; Liu H; Yan Z; Cao Z; Zhao H; He TC; Yu J; Shu Y; Zou L
    Leukemia; 2023 Oct; 37(10):1982-1993. PubMed ID: 37591940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
    Tan SH; Tan TK; Yokomori R; Liao M; Huang XZ; Yeoh AEJ; Sanda T
    Leukemia; 2023 Oct; 37(10):1969-1981. PubMed ID: 37591943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer. Cancer by super-enhancer.
    Vähärautio A; Taipale J
    Science; 2014 Dec; 346(6215):1291-2. PubMed ID: 25504702
    [No Abstract]   [Full Text] [Related]  

  • 14. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
    Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
    J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
    Astolfi A; Vendemini F; Urbini M; Melchionda F; Masetti R; Franzoni M; Libri V; Serravalle S; Togni M; Paone G; Montemurro L; Bressanin D; Chiarini F; Martelli AM; Tonelli R; Pession A
    Oncotarget; 2014 Jan; 5(1):120-30. PubMed ID: 24334727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoforms of the TAL1 transcription factor have different roles in hematopoiesis and cell growth.
    Sharma A; Mistriel-Zerbib S; Najar RA; Engal E; Bentata M; Taqatqa N; Dahan S; Cohen K; Jaffe-Herman S; Geminder O; Baker M; Nevo Y; Plaschkes I; Kay G; Drier Y; Berger M; Salton M
    PLoS Biol; 2023 Jun; 21(6):e3002175. PubMed ID: 37379322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.
    Sanda T; Leong WZ
    Exp Hematol; 2017 Sep; 53():7-15. PubMed ID: 28652130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia.
    Liau WS; Tan SH; Ngoc PCT; Wang CQ; Tergaonkar V; Feng H; Gong Z; Osato M; Look AT; Sanda T
    Leukemia; 2017 Aug; 31(8):1798-1807. PubMed ID: 28028313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia.
    Correia NC; Melão A; Póvoa V; Sarmento L; Gómez de Cedrón M; Malumbres M; Enguita FJ; Barata JT
    Oncotarget; 2016 Feb; 7(7):8268-81. PubMed ID: 26882564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
    Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
    Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.